RESEARCH TRIANGLE PARK — Synteract, a drug development company operating in Morrisville, has acquired Clindata’s human health biometrics division to meet market demand for more adaptable biometrics services solutions.
This acquisition extends Synteract’s existing global footprint into Asia Pacific and Africa, and offers another core biometrics services hub, complementary to those it operates in Europe and the U.S.
Clindata, with offices in Bloemfontein, South Africa, and Colombo, Sri Lanka, is a biometrics Clinical Research Organization, offering biostatistics, programming and data management services across all phases of drug development. Clindata’s Veterinary division will continue to operate under the Clindata name, independently from Synteract, while the Human Health Biometrics division will combine with Synteract.
“Like Synteract, Clindata is known for high quality service delivery, collaboration, agility and expertise of its teams,” says Synteract CEO Steve Powell, in a statement. “Innovative changes in biometrics are transforming the ways in which clinical study data is collected, integrated and analyzed. Rich patient data gives researchers insights into disease progression and response to therapy in ways we have not seen before. This is an exciting time to be adding even more expertise to our teams and will allow us to deliver global biometrics services covering every time-zone.”
Clindata CEO, Theo Erasmus, added: “With our combined biometrics capabilities, clients will benefit from a complete service offering incorporating all data components from research, advice on study design, document planning to PK analyses and results interpretation, as well as global capabilities, all provided by one integrated CRO. We are glad to be joining Synteract and creating a world class delivery team.”
Synteract is a portfolio company of Amulet Capital Partners, LP. Financial terms are not being disclosed.
Synteract has conducted nearly 4,000 studies on six continents and has contributed to more than 240 product approvals.